Inhibition of E-cadherin expression has been described in BRAF-driven thyroid tumors in which the MAPK pathway is activated [41], but little is known about the mechanisms involved in E-cadherin repression in RAS-driven tumors where PI3K/AKT is activated. Here, CDH1 is linked to thyroid tumor.